menu
    • menu

    Company profile for Soleno Therapeutics

    NEW Drugs in Dev: 2
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. We are committed to developing safe and effective therapeutic products that improve the lives of patients living with complex, life-threatening rare diseases with unmet medical needs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Soleno TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    203 Redwood Shores Parkway Suite 500 Redwood City, CA 94065
    Telephone
    Telephone
    (650) 213-8444
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://soleno.life/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Neurocrine Biosciences Completes Soleno Therapeutics Acquisition
    Neurocrine Biosciences Completes Soleno Therapeutics Acquisition

    18 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurocrine-biosciences-completes-acquisition-of-soleno-therapeutics-302774688.html

    PR NEWSWIRE
    18 May 2026
    Share Share
    Neurocrine Buys Soleno at Discount as Europe Prospects Fade
    Neurocrine Buys Soleno at Discount as Europe Prospects Fade

    21 Apr 2026

    // ENDPOINTS NEWS

    https://endpoints.news/soleno-sold-at-a-discount-to-neurocrine-due-to-dwindling-european-prospects/

    ENDPOINTS NEWS
    21 Apr 2026
    Share Share
    Robbins LLP Alerts SLNO Stockholders on Class Action
    Robbins LLP Alerts SLNO Stockholders on Class Action

    20 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-20/robbins-llp-encourages-slno-stockholders-to-contact-the-firm-for-information-about-the-class-action

    PHARMIWEB
    20 Apr 2026
    Share Share
    Folia Health Launches BRAVE-PWS Study for Prader-Willi Syndrome
    Folia Health Launches BRAVE-PWS Study for Prader-Willi Syndrome

    15 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/15/3274371/0/en/Folia-Health-Launches-BRAVE-PWS-Study-to-Better-Understand-the-Real-World-Experience-of-Prader-Willi-Syndrome-Caregivers.html

    GLOBENEWSWIRE
    15 Apr 2026
    Share Share
    Neurocrine expands into metabolic diseases with $2.9 billion Sole
    Neurocrine expands into metabolic diseases with $2.9 billion Sole

    06 Apr 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/neurocrine-buy-soleno-therapeutics-29-billion-2026-04-06/

    REUTERS
    06 Apr 2026
    Share Share
    SLNO Investors Sue Soleno Over Alleged Sham Trials
    SLNO Investors Sue Soleno Over Alleged Sham Trials

    17 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-17/slno-investor-alert-soleno-therapeutics-inc-securities-fraud-lawsuit-investors-with-losses-may

    PHARMIWEB
    17 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search